Conference Proceedings

BEACON: A Randomised, Phase 3 Study of Encorafenib and Cetuximab plus /- Binimetinib vs. Choice of Either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer Patients

Harpreet Wasan, Tobias Arkenau, Mike Braun, Leslie Samuel, Janet Graham, Scott Kopetz, Axel Grothey, Eric Van Cutsem, Rona Yaeger, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardello, Ashwin Gollerkeri, Kati Maharry, Victor Sandor, Janna Christy-Bittel, Lisa Anderson, Josep Tabernero

BRITISH JOURNAL OF CANCER | NATURE PUBLISHING GROUP | Published : 2019

Grants

Funding Acknowledgements

Funded by Array BioPharma, Boulder, US. was the Sponsor. Pierre Fabre Medicament, Paris, France, Merck KGaA, Darmstadt, Germany, Ono Pharmaceutical Co. Ltd. Osaka, Japan were 'Collaborators'